Ginkgo Bioworks Holdings (DNA) Capital Expenditures Growth (5y) (2025 - 2026)

Ginkgo Bioworks Holdings (DNA) Capital Expenditures Growth (5y) (2025 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,681.27 Bn 66,680.98 Bn -
2 Nanobiotix 1,905.61 Bn 1,905.55 Bn -
3 Akari Therapeutics 1,011.81 Bn 1,011.81 Bn -
4 BeOne Medicines 467.29 Bn 462.50 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.89 Bn 115.65 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.28 Bn 61.53 Bn 3.31 Bn
7 Belite Bio 62.93 Bn 62.93 Bn -
8 Argenx Se 55.90 Bn 50.72 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.64 Bn 34.63 Bn 959.66 Mn
10 Ginkgo Bioworks Holdings 439.28 Mn 295.42 Mn 16.38 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -14.92%
Dec 31, 2025 -80.85%